Acute Myelogenous Leukemia (AML) with Myelodysplastic Syndrome (MDS) or Therapy-Related AML, by FISH
Use in conjunction with conventional cytogenetics for diagnosis, prognosis, and monitoring in therapy-related MDS or AML associated with MDS. Use to establish and/or monitor for abnormal clone.
Fluorescence in situ Hybridization (FISH)
New York DOH Approval Status
Non-diluted bone marrow aspirate collected in a heparinized syringe. Also acceptable: Whole blood in green (sodium heparin).
Transfer bone marrow to a green (sodium heparin). Transport 3 mL bone marrow OR 5 mL whole blood. (Min: 1 mL bone marrow OR 2 mL whole blood)
Frozen specimens. Clotted or paraffin-embedded specimens.
Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Probes included: EGR1 (5q del), D7S486 (7q del/-7), MLL
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Analyte Specific Reagent (ASR)
A processing fee will be charged if this procedure is canceled, at the client's request, after the test has been set up, or if the specimen integrity is inadequate to allow culture growth. The fee will vary based on specimen type. To order probes separately, refer to Chromosome FISH, Interphase (2002298).
Other specimen types may be acceptable, contact the Cytogenetics Laboratory for specific specimen collection and transportation instructions.
If cell pellets or dropped cytogenetics slides are submitted, a processing fee will not apply.
This test must be ordered using Oncology test request form (#43099) or through your ARUP interface.
88271 x3; 88275 x3
|Component Test Code*||Component Chart Name||LOINC|
|2002654||AML with MDS, Therapy-Related AML, FISH||57802-1|
|2002655||EER AML with MDS, Therapy-Rltd AML, FISH||11526-1|